Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

BMC Nephrol 2009 Jan 21;10. Epub 2009 Jan 21.

Renal Unit, Royal Perth Hospital, Perth, WA, Australia.

Background: Haemodialysis (HD) is critically dependent on the availability of adequate access to the systemic circulation, ideally via a native arteriovenous fistula (AVF). The Primary failure rate of an AVF ranges between 20-54%, due to thrombosis or failure of maturation. There remains limited evidence for the use of anti-platelet agents and uncertainty as to choice of agent(s) for the prevention of AVF thrombosis. We present the study protocol for a randomised, double-blind, placebo-controlled, clinical trial examining whether the use of the anti-platelet agents, aspirin and omega-3 fatty acids, either alone or in combination, will effectively reduce the risk of early thrombosis in de novo AVF.

Methods/design: The study population is adult patients with stage IV or V chronic kidney disease (CKD) currently on HD or where HD is planned to start within 6 months in whom a planned upper or lower arm AVF is to be the primary HD access. Using a factorial-design trial, patients will be randomised to aspirin or matching placebo, and also to omega-3 fatty acids or matching placebo, resulting in four treatment groups (aspirin placebo/omega-3 fatty acid placebo, aspirin/omega-3 fatty acid placebo, aspirin placebo/omega-3 fatty acid, aspirin/omega-3 fatty acid). Randomisation will be achieved using a dynamic balancing method over the two stratification factors of study site and upper versus lower arm AVF. The medication will be commenced pre-operatively and continued for 3 months post surgery. The primary outcome is patency of the AVF at three months after randomisation. Secondary outcome measures will include functional patency at six and twelve months, primary patency time, secondary (assisted) patency time, and adverse events, particularly bleeding.

Discussion: This multicentre Australian and New Zealand study has been designed to determine whether the outcome of surgery to create de novo AVF can be improved by the use of aspirin and/or omega-3 fatty acids. Recently a placebo-controlled trial has shown that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. Our study presents significant differences in the anti-platelet agents used, the study design, and surgical and patient demographics that should contribute further evidence regarding the efficacy of anti-platelet agents.

Trial Registration: Australia & New Zealand Clinical Trials Register (ACTRN12607000569404).

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2369-10-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637871PMC
January 2009
4 Reads
1.520 Impact Factor

Publication Analysis

Top Keywords

fatty acids
16
omega-3 fatty
16
fatty acid
16
anti-platelet agents
12
avf thrombosis
12
lower arm
8
acid placebo
8
patency time
8
avf
8
aspirin placebo/omega-3
8
placebo/omega-3 fatty
8
matching placebo
8
avf primary
8
arm avf
8
aspirin/omega-3 fatty
8
fatty
8
functional patency
8
study
7
aspirin
6
primary
5

References

(Supplied by CrossRef)

M Allon et al.
Kidney Int 2002

KR Polkinghorne et al.
J Am Soc Nephrol 2004

S Pastan et al.
Kidney Int 2002

L Excell et al.
2004

B Manns et al.
J Am Soc Nephrol 2005

FK Port et al.
Clin J Am Soc Nephrol 2006

A Ishani et al.
Kidney Int 2005

A Asif et al.
Clin J Am Soc Nephrol 2006

PP Rooijens et al.
Eur J Vasc Endovasc Surg 2004

M Marshall et al.
2005

AN Sidawy et al.
J Vasc Surg 2002

Similar Publications